RedHill Biopharma Ltd.RDHL
Market cap
P/E ratio
| Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | |
| NET REVENUES | 4 | 8 | 6 | 64 | 86 | 62 | 7 | 8 |
| Cost of sales | 2 | 3 | 2 | 37 | 49 | 33 | 3 | 3 |
| GROSS PROFIT | 2 | 6 | 4 | 27 | 36 | 28 | 3 | 5 |
| RESEARCH AND DEVELOPMENT EXPENSES | 33 | 25 | 17 | 16 | 29 | 7 | 4 | 2 |
| Sales and marketing expense | 12 | 12 | 18 | 49 | 56 | 35 | 15 | 6 |
| GENERAL AND ADMINISTRATIVE EXPENSES | 8 | 8 | 11 | 25 | 32 | 29 | 16 | 10 |
| OTHER INCOME (EXPENSES) | -1 | - | - | - | - | - | 44 | -2 |
| OPERATING INCOME (LOSS) | -52 | -39 | -43 | -64 | -81 | -43 | 13 | -15 |
| Finance income | 7 | 1 | 1 | 0 | 0 | 14 | 21 | 8 |
| Finance costs | 0 | 0 | 0 | 13 | 17 | 42 | 10 | 2 |
| Financial income (expenses), net | - | - | - | - | - | - | - | 6 |
| INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS) FOR THE YEAR | -46 | -39 | -42 | -76 | -98 | -72 | 24 | -8 |
| LOSS PER ORDINARY SHARE, basic (U.S. dollars): | -0.26 | -0.17 | - | - | -0.21 | -0.12 | 0.01 | - |
| LOSS PER ORDINARY SHARE, diluted (U.S. dollars): | -0.26 | -0.17 | - | - | -0.21 | -0.12 | 0.01 | - |